Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

ICICI Securities SOUNDS ALARM: TCI Express BUY Rating & ₹900 Target Price Revealed! Don't Miss This Logistics Gem!

Brokerage Reports

|

Updated on 10 Nov 2025, 06:15 am

Whalesbook Logo

Reviewed By

Abhay Singh | Whalesbook News Team

Short Description:

ICICI Securities has issued a BUY recommendation for TCI Express with a target price of INR 900. The company's Q2FY26 EBITDA met expectations, with stable volumes and improved EBITDA margins driven by a price hike and cost efficiencies. TCI Express is expanding its branch network and plans significant capital expenditure through FY27, while management forecasts 10% revenue growth for FY26.
ICICI Securities SOUNDS ALARM: TCI Express BUY Rating & ₹900 Target Price Revealed! Don't Miss This Logistics Gem!

▶

Stocks Mentioned:

TCI Express Limited

Detailed Coverage:

ICICI Securities has maintained its BUY rating on TCI Express, setting a target price of INR 900 per share. The brokerage highlighted that TCI Express's Q2FY26 Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of INR 33.5 million was in line with market consensus. Volumes remained steady at 248 kilotons (kte), while EBITDA margin saw an improvement sequentially to 10.9% from 9.8% in Q1FY26, attributed to a 25 basis points price increase and effective cost management.

The company has expanded its network by adding 10 surface express branches and 25 rail network branches, leading to a capacity utilization increase to 83.5% from 82% in the previous quarter. TCI Express has invested INR 280 million in capital expenditure (capex) and plans to invest an additional INR 1.5 billion by the end of FY27. Management guidance for FY26 includes a 10% revenue growth, supported by an 8% volume increase and a 200 basis points price hike, with expectations of further EBITDA margin improvement.

Impact This research report from a reputable brokerage house, reiterating a BUY rating and a positive outlook, is likely to influence investor sentiment towards TCI Express. The clear growth drivers, expansion plans, and management's confidence can lead to increased investor interest and potentially drive the stock price towards the target of INR 900. Investors seeking exposure to the logistics sector may view this as a favorable investment opportunity. (Rating: 7/10)


Consumer Products Sector

Trent's Q2 Surprise: Sales Moderate, Margins Soar! New Brand & Expansion Fuel Future Growth

Trent's Q2 Surprise: Sales Moderate, Margins Soar! New Brand & Expansion Fuel Future Growth

Trent Stock Plunges 6%! Tata Retail Giant's Q2 Misses Expectations? Analysts Weigh In With Shocking Targets!

Trent Stock Plunges 6%! Tata Retail Giant's Q2 Misses Expectations? Analysts Weigh In With Shocking Targets!

LENSKART IPO FALLS FLAT! Eyewear Giant's Stock Debut Disappoints – Is This a Market Warning Sign?

LENSKART IPO FALLS FLAT! Eyewear Giant's Stock Debut Disappoints – Is This a Market Warning Sign?

Trent's Q2 Shock: Profit Drops, Brokerages Slash Targets! Is Your Investment Safe?

Trent's Q2 Shock: Profit Drops, Brokerages Slash Targets! Is Your Investment Safe?

Lenskart IPO Debuts Softly! Eyewear Giant Lists at Discount, What Investors Must Know

Lenskart IPO Debuts Softly! Eyewear Giant Lists at Discount, What Investors Must Know

Britannia's Stock Soars: Brokerage Upgrade Ignites 16% Upside with GST Boost!

Britannia's Stock Soars: Brokerage Upgrade Ignites 16% Upside with GST Boost!

Trent's Q2 Surprise: Sales Moderate, Margins Soar! New Brand & Expansion Fuel Future Growth

Trent's Q2 Surprise: Sales Moderate, Margins Soar! New Brand & Expansion Fuel Future Growth

Trent Stock Plunges 6%! Tata Retail Giant's Q2 Misses Expectations? Analysts Weigh In With Shocking Targets!

Trent Stock Plunges 6%! Tata Retail Giant's Q2 Misses Expectations? Analysts Weigh In With Shocking Targets!

LENSKART IPO FALLS FLAT! Eyewear Giant's Stock Debut Disappoints – Is This a Market Warning Sign?

LENSKART IPO FALLS FLAT! Eyewear Giant's Stock Debut Disappoints – Is This a Market Warning Sign?

Trent's Q2 Shock: Profit Drops, Brokerages Slash Targets! Is Your Investment Safe?

Trent's Q2 Shock: Profit Drops, Brokerages Slash Targets! Is Your Investment Safe?

Lenskart IPO Debuts Softly! Eyewear Giant Lists at Discount, What Investors Must Know

Lenskart IPO Debuts Softly! Eyewear Giant Lists at Discount, What Investors Must Know

Britannia's Stock Soars: Brokerage Upgrade Ignites 16% Upside with GST Boost!

Britannia's Stock Soars: Brokerage Upgrade Ignites 16% Upside with GST Boost!


Healthcare/Biotech Sector

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Sun Pharma's US Breakthrough: Specialty Drugs Now Lead Revenue, Ditching Generic Image!

Sun Pharma's US Breakthrough: Specialty Drugs Now Lead Revenue, Ditching Generic Image!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Sun Pharma's US Breakthrough: Specialty Drugs Now Lead Revenue, Ditching Generic Image!

Sun Pharma's US Breakthrough: Specialty Drugs Now Lead Revenue, Ditching Generic Image!